Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

ClinicalTrials.gov ID: NCT07502443

Public ClinicalTrials.gov record NCT07502443. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 (Brilliance NT2 Study 303)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.

Study identification

NCT ID
NCT07502443
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
176 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 21, 2026
Primary completion
Apr 30, 2027
Completion
May 31, 2027
Last update posted
Sep 2, 2026

2026 – 2027

United States locations

U.S. sites
22
U.S. states
14
U.S. cities
22
Facility City State ZIP Site status
Alkermes Investigational Site Cullman Alabama 35055 Recruiting
Alkermes Investigational Site Phoenix Arizona 85054 Recruiting
Alkermes Investigational Site Los Angeles California 90025 Recruiting
Alkermes Investigational Site Boulder Colorado 80301 Recruiting
Alkermes Investigational Site Brandon Florida 33511 Recruiting
Alkermes Investigational Site Maimi Florida 33176 Recruiting
Alkermes Investigational Site Winter Park Florida 32789 Recruiting
Alkermes Investigational Site Macon Georgia 31210 Recruiting
Alkermes Investigational Site Stockbridge Georgia 30281 Recruiting
Alkermes Investigational Site Kansas City Kansas 66160 Recruiting
Alkermes Investigational Site Newton Massachusetts 02459 Recruiting
Alkermes Investigational Site Lansing Michigan 48911 Not yet recruiting
Alkermes Investigational Site Novi Michigan 48377 Recruiting
Alkermes Investigational Site Charlotte North Carolina 28210 Recruiting
Alkermes Investigational Site Huntersville North Carolina 28078 Recruiting
Alkermes Investigational Site Cincinnati Ohio 45245 Recruiting
Alkermes Investigational Site Wyomissing Pennsylvania 19610 Recruiting
Alkermes Investigational Site Columbia South Carolina 29201 Recruiting
Alkermes Investigational Site Austin Texas 78731 Recruiting
Alkermes Investigational Site Frisco Texas 75033 Recruiting
Alkermes Investigational Site San Antonio Texas 78229 Recruiting
Alkermes Investigational Site Sugar Land Texas 77478 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07502443, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 2, 2026 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07502443 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →